eISSN: 2081-2841
ISSN: 1689-832X
Journal of Contemporary Brachytherapy
Current Issue Archive Supplements Articles in Press Journal Information Aims and Scope Editorial Office Editorial Board Register as Author Register as Reviewer Instructions for Authors Abstracting and indexing Subscription Advertising Information Links
SCImago Journal & Country Rank

vol. 10
Review paper

UK & Ireland Prostate Brachytherapy Practice Survey 2014-2016

Gemma Corey, A.B. Mohamed Yoosuf, Geraldine Workman, Monica Byrne, Darren M. Mitchell, Suneil Jain

J Contemp Brachytherapy 2018; 10, 3: 238–245
Online publish date: 2018/06/29
View full text
Get citation
JabRef, Mendeley
Papers, Reference Manager, RefWorks, Zotero
To document the current prostate brachytherapy practice across the UK and Ireland and compare with previously published audit results.

Material and methods
Participants from 25 centers attending the annual UK & Ireland Prostate Brachytherapy Conference were invited to complete an online survey. Sixty-three questions assessed the center’s experience and staffing, clinician’s experience, clinical selection criteria and scheduling, number of cases per modality in the preceding three years, low-dose-rate (LDR) pre- and post-implant technique and high-dose-rate (HDR) implant technique. Responses were collated, and descriptive statistical analysis performed.

Eighteen (72%) centers responded with 17 performing LDR only, 1 performing HDR only, and 6 performing both LDR and HDR. Seventy-one percent of centers have > 10 years of LDR brachytherapy experience, whereas 71% centers that perform HDR brachytherapy have > 5 years of experience. Thirteen centers have 2 or more clinicians performing brachytherapy with 61% of lead consultants performing > 25 cases (LDR + HDR) in 2016. The number of implants (range), that includes LDR and HDR, performed by individual practitioners in 2016 was > 50 by 21%, 25-50 by 38%, and < 25 by 41%. Eight centers reported a decline in LDR monotherapy case numbers in 2016. Number of center’s performing HDR brachytherapy increased in last five years. Relative uniformity in patient selection is noted, and LDR pre- and post-implant dosimetry adheres to published quality guidelines, with an average post-implant D90 of > 145 Gy in 69% of centers in 2014 and 2015 compared to 63% in 2016. The median CT/US volume ratios were > 0.9 ≤ 1.0 (n = 4), > 1.0 ≤ 1.1 (n = 7), and > 1.1 (n = 2).

There is considerable prostate brachytherapy experience in the UK and Ireland. An apparent fall in LDR case numbers is noted. Maintenance of case numbers and ongoing compliance with published quality guidelines is important to sustain high quality outcomes.


LDR prostate brachytherapy, HDR prostate brachytherapy, UK & Ireland

Zaorsky NG, Davis BJ, Nguyen PL et al. The evolution of brachytherapy for prostate cancer. Nat Rev Urol 2017; 14:
Davis BJ, Horwitz EM, Lee WR et al. American Brachytherapy Society consensus guidelines for transrectal ultrasound-guided permanent prostate brachytherapy. Brachytherapy 2012; 11: 6-19.
Yamada Y, Rogers L, Demanes DJ et al. American Brachytherapy Society consensus guidelines for high-dose-rate prostate brachytherapy. Brachytherapy 2012; 11: 20-32.
Salembier C, Lavagnini P, Nickers P et al. Tumour and target volumes in permanent prostate brachytherapy: a  supplement to the ESTRO/EAU/EORTC recommendations on prostate brachytherapy. Radiother Oncol 2007; 83: 3-10.
Hoskin PJ, Colombo A, Henry A  et al. GEC/ESTRO recommendations on high dose rate afterloading brachytherapy for localised prostate cancer: an update. Radiother Oncol 2013; 107: 325-332.
The Royal College of Radiologists: Quality Assurance Practice guidelines for transperineal LDR permanent seed brachytherapy of prostate cancer. The Royal College of Radiologist, London 2012.
Zaorsky NG, Shaikh T, Murphy CT et al. Comparison of outcomes and toxicities among radiation therapy treatment options for prostate cancer. Cancer Treat Rev 2016; 48: 50-60.
Hoskin PJ, Rojas AM, Bownes PJ et al. Randomised trial of external beam radiotherapy alone or combined with high-dose-rate brachytherapy boost for localised prostate cancer. Radiother Oncol 2012; 103: 217-222.
Spratt DE, Soni PD, McLaughlin PW et al. American Brachytherapy Society Task Group Report: Combination of brachytherapy and external beam radiation for high-risk prostate cancer. Brachytherapy 2017; 16: 1-12.
Lee CD. Recent Developments and best practice in brachytherapy treatment planning. Br J Radiol 2014; 87: 20140146.
Petereit DG, Frank SJ, Viswanathan AN et al. Brachytherapy: where has it gone? J Clin Oncol 2015; 33: 980-982.
Copperberg MJ, Broering JM, Carroll PR. Time trends and local variation in primary treatment of localised prostate cancer. J Clin Oncol 2010; 28: 1117-1123.
Stewart AJ, Drinkwater KJ, Laing RW et al. The Royal College of Radiologists’ Audit of Prostate Brachytherapy in the Year 2012. Clin Oncol 2015; 27: 330-336.
Prestidge BR, Prete JJ, Buchholz TA et al. Survey of current clinical practice of permanent prostate brachytherapy in the United States. Int J Radiat Oncol Biol Phys 1998; 40: 461-465.
Buyyounouski MK, Davis BJ, Prestidge BR et al. A  survey of current clinical practice in permanent and temporary prostate brachytherapy: 2010 Update. Brachytherapy 2012; 11: 299-305.
Crook J. Long-term oncologic outcomes of radical prostatectomy compared with brachytherapy-based approaches for intermediate- and high-risk prostate cancer. Brachytherapy 2015; 14: 142-147.
D’Amico AV, Whittington R, Malkowicz SB et al. Biochemical outcome after radical prostectomy, external beam radiation therapy or interstitial radiation therapy for clinically localized prostate cancer. JAMA 1998; 280: 969-974.
Royal College of Radiologists. The role and development of brachytherapy services in the United Kingdom. Royal College of Radiologists, London 2007.
Zaorsky NG, Doyle LA, Yamoah K et al. High dose rate brachytherapy boost for prostate cancer: a  systematic review. Cancer Treat Rev 2014; 40: 414-425.
Morris WJ, Tyldesley S, Rodda S et al. Androgen Suppression Combined with Elective Nodal and Dose Escalated Radiation Therapy (the ASCENDE-RT Trial): An Analysis of Survival Endpoints for a  Randomized Trial Comparing a  Low-Dose-Rate Brachytherapy Boost to a  Dose-Escalated External Beam Boost for High- and Intermediate-risk Prostate Cancer. Int J Radiat Oncol Biol Phys 2017; 98: 275-285.
Rodda S, Tyldesley S, Morris WJ et al. ASCENDE-RT: An Analysis of Treatment-Related Morbidity for a  Randomized Trial Comparing a  Low-Dose-Rate Brachytherapy Boost with a  Dose-Escalated External Beam Boost for High- and Intermediate-Risk Prostate Cancer. Int J Radiat Oncol Biol Phys 2017; 98: 286-295.
Dearnaley D, Syndikus I, Mossop H et al. Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: 5-year outcomes of the randomised, non-inferiority, phase 3 CHHiP trial. Lancet Oncol 2016; 17: 1047-1060.
Musunuru HB, Loblaw A. Clinical trials of stereotactic ablative radiotherapy for prostate cancer: updates and future direction. Future Oncol 2015; 11: 819-831.
Morton GC, Hoskin PJ. Brachytherapy: current status and future strategies – can high dose rate replace low dose rate and external beam radiotherapy? Clin Oncol 2013; 25: 474-482.
Morton GC, Loblaw DA, Chung H et al. Health-related quality of life after single-fraction high-dose-rate brachytherapy and hypofractionated external beam radiotherapy for prostate cancer. Int J Radiat Oncol Biol Phys 2011; 80: 1299-1305.
Orio PF 3rd, Nguyen PL, Buzurovic I  et al. Prostate Bra­ chy­ therapy Case Volumes by Academic and Nonacademic Practices: Implications for Future Residency Training. Int J Radiat Oncol Biol Phys 2016; 96: 624-628.
Morris WJ, Tyldesley S, Pai HH et al. ASCENDE‑ RT: A  multicenter, randomized trial of dose-escalated external beam radiation therapy (EBRT‑ B) versus low-dose-rate brachytherapy (LDR‑ B) for men with unfavorable-risk localized prostate cancer. J Clin Oncol 2015; 33 (Suppl 7), abstr.
Shen X, Keith SW, Mishra MV et al. The impact of brachytherapy on prostate cancer-specific mortality for definitive radiation therapy of high-grade prostate cancer: a  population-based analysis. Int J Radiat Oncol Biol Phys 2012; 83: 1154-1159.
Hoskin P, Rojas A, Ostler P et al. High-dose-rate brachytherapy with two or three fractions as monotherapy in the treatment of locally advanced prostate cancer. Radiother Oncol 2014; 112: 63-67.
Bice WS, Prestidge BR, Kurtzman SM et al. Recommendations for permanent prostate brachytherapy with 131Cs: a  consensus report from the Cesium Advisory Group. Brachytherapy 2008; 7: 290-296.
Demanes D J, Martinez AA, Ghilezan M et al. High-dose-rate monotherapy: safe and effective brachytherapy for patients with localized prostate cancer. Int J Radiat Oncol Biol Phys 2011; 81: 1286-1292.
Ghadjar P, Keller T, Rentsch CA et al. Toxicity and early treatment outcomes in low- and intermediate-risk prostate cancer managed by high-dose-rate brachytherapy as a  monotherapy. Brachytherapy 2009; 8: 45-51.
Hoskin P, Rojas A, Lowe G et al. High-dose-rate brachytherapy alone for localized prostate cancer in patients at moderate or high risk of biochemical recurrence. Int J Radiat Oncol Biol Phys 2012; 82: 1376-1384.
Grimm P, Billiet I, Bostwick D et al. Comparative analysis of prostate specific antigen free survival outcomes for patients with low, intermediate and high risk prostate cancer treatment by radical therapy. Results from the Prostate Cancer Results Study Group. BJU Int 2012; 109 Suppl 1: 22-29.
Prestidge BR, Winter K, Sanda MG et al. Initial Report of NRG Oncology/RTOG 0232: a  phase III study comparing combined external beam radiation and transperineal interstitial permanent brachytherapy with brachytherapy alone for selected patients with intermediate risk prostatic carcinoma. Int J Radiat Oncol Biol Phys 2016; 96 Suppl 4: 4.
Serrano N, Moghanaki D, Asher D et al. Comparative study of late rectal toxicity in prostate cancer patients treated with low-dose-rate brachytherapy: with or without supplemental external beam radiotherapy. Brachytherapy 2016; 15: 435-441.
Quick links
© 2019 Termedia Sp. z o.o. All rights reserved.
Developed by Bentus.
PayU - płatności internetowe